MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why XRAY Stock advanced +1.80% Today — RQD Quant Desk Flash
$9.61 +1.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $9.62
DENTSPLY SIRONA Inc. (XRAY) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.92B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $9.62 (+0.13%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 6.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XRAY)Realized 20D OHLCV Swing Band: ±7.8%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY XRAY SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (30% of score)
20D Institutional Volume Accumulation (±7.8% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)
FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 55.1 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk5/20 pts (-15 pt drag)
Balance-sheet & 10-K footnote risk deducts 15 pts from forensic ceiling
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$8.83-2.9% Next Q
38
Q2 (-2Q)Grade D$8.57+10% Next Q
41
Q3 (-1Q)Grade D$9.43+1.9% Next Q
43
CurrentGrade D$9.61-6.1% Hist 90D α
46
Trajectory: E (38) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a XRAY Turnaround Squeeze
While XRAY currently carries a cautious 46/100 (D) rating due to SEC 10-K Forensic Risk (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.70) and Max Pain ($10.09) forces dealer call-delta covering toward $15.50.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $XRAY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XRAY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why XRAY Stock advanced +1.80% Today — RQD Quant Desk Flash
DENTSPLY SIRONA Inc. (XRAY) advanced +1.80% to $9.61, trading at 20% of its 52-week range ($8.32 – $14.76). Stretched risk/reward at current multiples (-11% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 20% of its 52-week range ($8.32 – $14.76) with RSI-14 at 55.1 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.8% around $9.61 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 50% gross margin and $235.0M annual free cash flow.
Live XRAY Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XRAY)
- ✓Walkthrough of XRAY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
XRAY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.21%📐 HORIZONTAL RANGE
2026-10-30O $9.55H $9.68L $9.41C $9.61VOL 3.50M
RES: $11.64SUP: $8.20SMA50: $9.70SMA200: $11.33
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
XRAY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -3.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on XRAY today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for XRAY. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XRAY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XRAY)
Health Care Rank #441 of 1016
⚔️ LMAT vs XRAY Full Matrix →
1. Head-to-Head Health Care Peer Comparison (XRAY vs. LMAT, KMTS, INSP, ATEC)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, DENTSPLY SIRONA Inc. (XRAY) ranks #441 by composite RQD confidence (46/100, grade D) and #269 by equity capitalization ($1.92B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. LMAT currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with XRAY at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XRAY
ACTIVE
DENTSPLY SIRONA Inc. | D | 46/100 | — | 50.0% | -11.0% | +1.80% | $1.92B | Benchmark Subject |
| LMAT LeMaitre Vascular Inc. | B | 74/100 | 33.8x | 71.5% | 14.7% | +2.90% | $1.95B | /lmat-vs-xray → |
| KMTS Kestra Medical Technologies Ltd. | D- | 43/100 | — | 51.4% | -35.0% | +2.48% | $1.82B | /kmts-vs-xray → |
| INSP Inspire Medical Systems Inc. | C- | 61/100 | 14.2x | 85.4% | 6.0% | +0.30% | $2.06B | /insp-vs-xray → |
| ATEC Alphatec Holdings Inc. | D- | 38/100 | — | 69.6% | -18.4% | -0.70% | $1.76B | /atec-vs-xray → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000818479In its most recent audited fiscal period (FY2025, filed 2025-12-31), DENTSPLY SIRONA Inc. (XRAY) reported GAAP revenue of $3.68B (-3.0% vs. FY2024 revenue of $3.79B , and -7.2% cumulative change since FY2023) , GAAP net income of -$598.0M, operating cash flow of $235.0M, and free cash flow of $235.0M (-49.0% YoY). On the balance sheet, XRAY closed FY2025 with $5.43B in total assets against $2.02B in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.68B | -$598.0M | $235.0M | $235.0M | $5.43B | $2.02B |
| FY2024 (FY) | 2024-12-31 | $3.79B | -$910.0M | $461.0M | $461.0M | $5.75B | $1.59B |
| FY2023 (FY) | 2023-12-31 | $3.96B | -$132.0M | $377.0M | $377.0M | — | — |
3. XRAY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs XRAY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, DENTSPLY SIRONA Inc. (NASDAQ: XRAY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $9.61 (+1.80% 1D, market cap $1.92B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, XRAY ranks #441 in composite RQD confidence.
How does XRAY compare to LMAT and KMTS in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), XRAY carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 50.0%, and ROIC of -11.0%. By comparison, LMAT (LeMaitre Vascular Inc.) holds a B grade (74/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.95B) and KMTS (Kestra Medical Technologies Ltd.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.82B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for XRAY?
Per XRAY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818479), DENTSPLY SIRONA Inc. generated $3.68B in revenue (-3.0% YoY), -$598.0M in net income, and $235.0M in free cash flow against $5.43B in total assets and $2.02B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is XRAY trading relative to its 50-day, 200-day, and 52-week technical levels?
XRAY last traded at $9.61 (+1.80% on volume of 3,552,540 shares), positioning the stock -0.93% below its 50-day simple moving average ($9.70) and -15.18% below its 200-day simple moving average ($11.33). Across its 52-week range of $8.32 to $14.76, XRAY sits at the 20.0% percentile with a 14-day RSI of 55.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.8% ($8.86 to $10.36).
XRAY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is XRAY stock moving today?
Why XRAY Stock advanced +1.80% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-11% return on capital) under elevated 10-year interest-rate pressure.